Chambers and Partners, the world's leading legal directory, recently published its Life Sciences Global Practice Guide (2025) (the "Guide"). Han Kun again contributed the China chapter of the Guide's Trends and Developments section. The contributors include Min Zhu, Michelle Y. Gon, Yang (Aaron) Gu, Lu Chai, Dr. Ying Li, and Shiye Yuan.
The Guide features close to 20 jurisdictions and provides the latest information on the regulatory framework for life sciences; clinical trials; the marketing, manufacturing and distribution of pharmaceuticals and medical devices; their import, export and pricing; and regulatory reliance and fast-track registration. The Guide's China chapter covers major changes in venture capital/private equity financing, mergers and acquisitions, and license-in/out and Newco model deals in the life sciences industry; regulatory developments in foreign direct investment, clinical trials, human genetic resources, and drug and medical devices; compliance practices in respect of commercial bribery and medical insurance fund usage; and patent applications, examinations, and industrialization and tax incentives for the life sciences industry.
Han Kun has a dedicated life sciences and healthcare team and has been consistently ranked as a leading law firm in the life sciences and healthcare sector by authoritative legal directories, including Chambers and Partners, The Legal 500, Asialaw Profiles, and China Business Law Journal. The firm is committed to providing clients in the life sciences and healthcare sector with comprehensive legal services, including private equity and venture capital, mergers and acquisitions, onshore and offshore capital markets, pharmaceutical license in/out, and asset sale/purchase transactions, intellectual property, compliance and regulatory, data protection, and dispute resolution.
